Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 3, 2022
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
[ Thu, Feb 03rd 2022
] - WOPRAI
Mani Foroohar Maintained (ARWR) at Hold with Decreased Target to $36 on, Feb 3rd, 2022
Mani Foroohar of SVB Leerink, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold with Decreased Target from $46 to $36 on, Feb 3rd, 2022.
Mani has made no other calls on ARWR in the last 4 months.
There is 1 other peer that has a rating on ARWR. Out of the 1 peers that are also analyzing ARWR, 0 agree with Mani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mani
- Madhu Kumar of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Wednesday, January 19th, 2022
